Newsroom

Download PDF — AVEO to Receive $125 Million Upfront and $1.3 Billion in Potential Milestones —— Global 50/50 Profit Share with AVEO to Lead Commercialization in North America and Astellas to Lead Commercialization in Europe —— Agreement Accelerates Development of Tivozanib in Multiple Additional Cancer Indications — TOKYO & CAMBRIDGE, Mass., Feb 16, 2011 (BUSINESS

Download PDF CAMBRIDGE, Mass., Feb 16, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated 2010 financial results and reviewed key 2010 accomplishments. “Last year was a transformational year for AVEO with our initial public offering, rapid enrollment of our pivotal

Download PDF CAMBRIDGE, Mass., Feb 14, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster

Download PDF CAMBRIDGE, Mass., Feb 10, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2010 will be released after the market closes on Wednesday, February 16, 2011. The AVEO management team will host a conference call discussing the company’s

Download PDF CAMBRIDGE, Mass., Feb 03, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name “ficlatuzumab” (pronounced fye” kla tue’ zue mab) for

Download PDF CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell

Download PDF CAMBRIDGE, Mass., Jan 21, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported positive data from its Phase 1b clinical trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in combination with FOLFOX6, a standard chemotherapy regimen,

Download PDF CAMBRIDGE, Mass., Jan 04, 2011 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco. Mr.